Market Overview

UPDATE: Canaccord Genuity Raises PT to $10 on Synergy Pharmaceuticals on Positive Plecanatide Data

Related SGYP
1 Way To Search For The 'Next Big Thing' In Biotech
Benzinga's Top #PreMarket Gainers
Patient enrollment complete in Phase 3 plecanatide trial (Seeking Alpha)

Canaccord Genuity reiterated its Buy rating on Synergy Pharmaceuticals (NASDAQ: SGYP) and increased its price target from $7 to $10.

Canaccord Genuity noted, "Reiterate BUY, raise target to $10 on increased probability of success for plecanatide in CIC. We see clear unmet need in chronic constipation (CIC) patients who don't respond/have AEs on current therapies. Compared to Linzess (FRX/IRWD), plecanatide may have better tolerability (no diarrhea in Phase 2a). We are raising our pNPV based target to $10 from $7, driven by increased chance of plecanatide success on today's positive proof of concept data."

Synergy Pharmaceuticals closed at $5.26 on Monday.

Latest Ratings for SGYP

Jan 2015CitigroupMaintainsBuy
Oct 2014Cantor FitzgeraldMaintainsBuy
Nov 2013Canaccord GenuityReiteratesBuy

View More Analyst Ratings for SGYP
View the Latest Analyst Ratings

Posted-In: Canaccord GenuityAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (SGYP)

Around the Web, We're Loving...

Get Benzinga's Newsletters